ATE274353T1 - Verwendung von aufgereinigtem invaplex als impfstoff für gram-negativebakterien - Google Patents

Verwendung von aufgereinigtem invaplex als impfstoff für gram-negativebakterien

Info

Publication number
ATE274353T1
ATE274353T1 AT99969665T AT99969665T ATE274353T1 AT E274353 T1 ATE274353 T1 AT E274353T1 AT 99969665 T AT99969665 T AT 99969665T AT 99969665 T AT99969665 T AT 99969665T AT E274353 T1 ATE274353 T1 AT E274353T1
Authority
AT
Austria
Prior art keywords
negative bacteria
vaccine
gram negative
invaplex
purified
Prior art date
Application number
AT99969665T
Other languages
English (en)
Inventor
Edwin V Oaks
Kevin Ross Turbyfill
Antoinette Berrong Hartman
Original Assignee
Us Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27379338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE274353(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Army filed Critical Us Army
Application granted granted Critical
Publication of ATE274353T1 publication Critical patent/ATE274353T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/50—Lipopolysaccharides; LPS
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT99969665T 1998-09-30 1999-09-28 Verwendung von aufgereinigtem invaplex als impfstoff für gram-negativebakterien ATE274353T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10239898P 1998-09-30 1998-09-30
US10239798P 1998-09-30 1998-09-30
US13619099P 1999-05-27 1999-05-27
PCT/US1999/022772 WO2000018355A2 (en) 1998-09-30 1999-09-28 Use of purified invaplex from gram negative bacteria as a vaccine

Publications (1)

Publication Number Publication Date
ATE274353T1 true ATE274353T1 (de) 2004-09-15

Family

ID=27379338

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99969665T ATE274353T1 (de) 1998-09-30 1999-09-28 Verwendung von aufgereinigtem invaplex als impfstoff für gram-negativebakterien

Country Status (6)

Country Link
US (4) US6245892B1 (de)
EP (1) EP1198245B1 (de)
AT (1) ATE274353T1 (de)
AU (2) AU1199900A (de)
DE (1) DE69919754T2 (de)
WO (2) WO2000018355A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU734532B2 (en) * 1996-04-19 2001-06-14 Henry M. Jackson Foundation For The Advancement Of Military Medicine Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
US7172762B1 (en) * 1999-01-29 2007-02-06 Pfizer Inc. Erysipelothrix rhusiopathiae antigens and vaccine compositions
GB0025058D0 (en) * 2000-10-12 2000-11-29 Smithkline Beecham Biolog Composition
DE60218662T2 (de) * 2001-05-18 2007-11-08 Walter Reed Army Institute Of Research Heterologer schutz, induziert durch immunisierung mit der invaplex-vakzine
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP1582217A1 (de) * 2002-11-14 2005-10-05 Instituto Finlay, Centro de Investigacion-Produccion de vacunas y sueros Verfahren zum erhalt von konjugatimpfstoffen und impfstoffzusammensetzungen mit denselben
US20090226397A1 (en) 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
DK2198876T3 (da) * 2003-10-24 2013-03-11 Nora Therapeutics Inc Fremgangsmåde til nedsættelse af sandsynligheden for implantationssvigt i et individ
US8338373B2 (en) * 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
CA2548202C (en) * 2003-11-25 2013-05-14 The Government Of The United States, As Represented By The Secretary Of The Army Use of shigella invaplex to transport functional proteins and transcriptionally active nucleic acids across mammalian cell membranes in vitro and in vivo
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US7833740B2 (en) * 2005-08-07 2010-11-16 Tgc Biomics Gmbh Test system for detecting salmonella
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
CA2563214A1 (en) * 2006-10-12 2008-04-12 Institut Pasteur Shigella ipad protein and its use as a potential vaccine against shigella infection
US7780966B2 (en) * 2007-03-27 2010-08-24 The United States Of America As Represented By The Secretary Of The Army Artificial invaplex
CA2685729C (en) * 2007-03-27 2016-05-31 The United States Of America As Represented By The Secretary Of The Army, Walter Reed Army Institute Of Research Artificial invaplex
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
RU2580620C2 (ru) * 2010-08-23 2016-04-10 ВАЙЕТ ЭлЭлСи СТАБИЛЬНЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Neisseria meningitidis rLP2086
PE20140173A1 (es) 2010-09-10 2014-02-20 Wyeth Llc Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
BR112015004775A2 (pt) * 2012-09-06 2017-11-21 Eveliqure Biotechnologies Gmbh vacina de shigella viva atenuada, cepa de shigella mutada e vetor plasmídeo recombinante com base em um plasmídeo de invasão de shigella mutado
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
EP2964665B1 (de) 2013-03-08 2018-08-01 Pfizer Inc Immunogene fusionspolypeptide
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
CN107249626A (zh) 2015-02-19 2017-10-13 辉瑞大药厂 脑膜炎奈瑟球菌组合物及其方法
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
CN112831487B (zh) * 2021-01-27 2022-05-06 武汉爱博泰克生物科技有限公司 一种重组蛋白酶k的纯化方法及其应用
CN113466321B (zh) * 2021-08-12 2022-10-14 河北省食品检验研究院 一种产志贺毒素大肠埃希氏菌的分型方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US5589380A (en) * 1992-06-05 1996-12-31 University Of Maryland At Baltimore Isolated DNA molecule encoding SHET1 of Shigella flexneri 2a and mutant Shigella flexneri 2a
US5897475A (en) * 1994-10-05 1999-04-27 Antex Biologics, Inc. Vaccines comprising enhanced antigenic helicobacter spp.
US5972899A (en) * 1996-01-25 1999-10-26 New York University Apoptosis induced by Shigella IpaB
DE69736226T2 (de) * 1996-04-19 2006-11-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Verfahren zur anregung einer immunantwort durch verabreichung von nutzorganismen, die intimin allein oder als fusionsprotein mit einem oder mehreren anderen antigenen exprimieren
US6342352B1 (en) * 1998-04-24 2002-01-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of detecting shigella and shigella mxiM DNA

Also Published As

Publication number Publication date
WO2000018355A9 (en) 2001-08-16
DE69919754T2 (de) 2005-09-01
WO2000018355A3 (en) 2000-11-23
EP1198245B1 (de) 2004-08-25
US20050013822A1 (en) 2005-01-20
DE69919754D1 (de) 2004-09-30
US20010009957A1 (en) 2001-07-26
AU1098400A (en) 2000-04-17
AU1199900A (en) 2000-04-17
US6680374B2 (en) 2004-01-20
WO2000018354A2 (en) 2000-04-06
US6277379B1 (en) 2001-08-21
US6245892B1 (en) 2001-06-12
EP1198245A2 (de) 2002-04-24
WO2000018355A2 (en) 2000-04-06
WO2000018354A3 (en) 2001-01-04

Similar Documents

Publication Publication Date Title
ATE274353T1 (de) Verwendung von aufgereinigtem invaplex als impfstoff für gram-negativebakterien
KR950700894A (ko) 탁솔 유도체(Taxol derivatives)
NZ618298A (en) A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
DE69731285D1 (de) Langwellig fluorezierende proteine
IT1293778B1 (it) 1,4,7,10-tetraazabiciclo(8.2.2.)tetradecan-2 one, sua preparazione e suo uso per la preparazione di tetraazamacrocicli
ES2143666T3 (es) P-amidinobencilamidas dipeptidicas con restos sulfonilo, o bien aminosulfonilo n-terminales.
NO974322D0 (no) DNA som koder for human papillomvirus type 18
DE69527986T2 (de) Antigene arznei zur behandlung oder vorbeugung
DK0840792T3 (da) (S)-hydroxynitrillyase fra Hevea brasiliensis
DK1395283T3 (da) Heterolog beskyttelse induceret ved immunisering med Invaplex-vaccine
DK0786004T3 (da) Kloning, ekspression og karakterisering af en hidtil ukendt form af phosphatidylinositol-3-kinase
DE69728897D1 (de) Saeugetierchemokine
ATE92498T1 (de) Primycinkomponenten und verfahren zur trennung des antibiotischen komplexes.
TR199701298T1 (xx) Tetralinler.
AU8405798A (en) A swine hepatitis e virus and uses thereof
ATE294237T1 (de) S?ugetier thymokingene
DE69131665T2 (de) Gen-expressionssystem
ATE376586T1 (de) Ppgpp-synthetase und expressionssysteme zur verbesserten herstellung von proteinen
DE60114608D1 (de) Verfahren zur herstellung von anthracyclinederivaten
ID28174A (id) Turunan 5-imino-13-deoksi antrasiklin, penggunaannya, dan proses pembuatannya
ZA9601216D (en) Novel Antigen.
DE69104357D1 (de) Klonierungs- und/oder expressionsvektoren, verfahren zur ihrer herstellung und verwendung.
YU30198A (sh) Prečišćavanje propilen oksida
PL347673A1 (en) 1,4-diaryl-2-fluoro-1-buten-3-ol compounds and their use in the preparation of 1,4-diaryl-2-fluoro-1,3-butadiene and 1,4-diaryl-2-fluoro-2-butene compounds
SU1826520A1 (ru) Штамм бактерий bacillus polymyxa - продуцент полисахарида

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties